New Drug Target for Remyelination in Multiple Sclerosis

Updated August 15, 2018

Research by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology has found that a receptor called muscarinic type 3 (M3R), a key regulator of the remyelination process, is a promising drug target in the treatment of multiple sclerosis. “This work establishes that M3R has a functional role and if blocked, could improve myelin repair,” he said. “It better positions the field for clinical trials that will be aimed at blocking these receptors in MS patients.”